Orexigen Therapeutics (OREX) Reports Q2 Loss of $2.00/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Orexigen Therapeutics Announces Second Quarter 2017 Financial Results
August 8, 2017 4:01 PM EDTSAN DIEGO, Aug. 8, 2017 /PRNewswire/ --Â Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the second quarter ended June 30, 2017.
"Our performance in the second quarter of 2017 reflects the successful implementation of our commercial strategy that we launched late last year. Â The team at Orexigen has delivered dramatic growth of U.S. Contrave sales in the first half of 2017," said Mike Narachi, President and Chief Executive Officer of Orexigen. Â He continued, "In addition to delivering strong growth from an innovative and highly-efficient primary care model, we have... More
